LDHA and neoplasm: It is worth noting that in the clinical trial of LDHA inhibitors combined with T-cell immunotherapy, a variety of different strategies should be adopted to enhance the efficacy, such as targeting the inhibition of LDHA in tumors and regulating the TME to increase the T-cell antitumor response, targeting LDHA in T cells to enhance the efficacy of ACT, and simultaneous treatment of tumor cells and T cells with LDHA inhibitors to enhance the antitumor efficacy (Figure 4).